"the review of the data from our investigations was as expected.”
Prescient is responding to the US FDA with data on its two other studies of PTX-200 in patients with breast and ovarian cancer.
So, as predicted on a probability factor by our chief investigator.
And, (as previously posted) and assessment of 'benefit/risk' ratio still awaiting decision by the FDA on the current holds.
Upon, hopeful resumption of all trials, a stronger buy would more obviously by implied.
Of course, all in my opinion.
